MI-2 [MALT1 Inhibitor]
| Code | Size | Price |
|---|
| AG-CR1-3661-M005 | 5 mg | £90.00 |
Quantity:
| AG-CR1-3661-M025 | 25 mg | £330.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Storage:
Short Term: +4°C. Long Term: -20°C
Documents
Further Information
Alternate Names/Synonyms:
2-Chloro-N-[4-[5-(3,4-dichlorophenyl)-3-(2-methoxyethoxy)-1H-1,2,4-triazol-1-yl]phenylacetamide; ALB-H03200218
Appearance:
White to off-white solid.
CAS:
1047953-91-2
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07
Handling Advice:
Keep cool and dry.
Hazards:
H315, H319, H335
InChi:
InChI=1S/C19H17Cl3N4O3/c1-28-8-9-29-19-24-18(12-2-7-15(21)16(22)10-12)26(25-19)14-5-3-13(4-6-14)23-17(27)11-20/h2-7,10H,8-9,11H2,1H3,(H,23,27)
InChiKey:
TWJGQZBSEMDPQP-UHFFFAOYSA-N
Long Description:
Chemical. CAS: 1047953-91-2. Formula: C19H17Cl3N4O3. MW: 455.7. Synthetic. Highly potent and selective irreversible MALT1 inhibitor (IC50=5.8µM). Binds directly to MALT1 and suppresses protease function. Decreases NF-kappaB activity induced by MALT1. Inhibits cell proliferation and MALT1-mediated cleavage activity. Suppresses human TMD8 and HBL-1 (EC50= ~200nM and ~500nM for HBL-1 and TMD8, respectively) activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines in vitro and xenotransplanted mouse ABC-DLBCL tumors in vivo and primary human ABC-DLBCLs ex vivo. In combination with bryostatin 1 displays selective killing of HIV latently infected CD4+ T cells. Inhibits NF-kappaB and NLRP3 inflammasome activation in macrophages. Decreased production of IL-1beta/IL-18 in PMA-differentiated THP-1 cells and bone marrow derived macrophage via suppressing the activation of NF-kappaB and NLRP3 inflammasome.
MDL:
MFCD19754074
Molecular Formula:
C19H17Cl3N4O3
Molecular Weight:
455.7
Package Type:
Plastic Vial
Precautions:
P302, P352, P304, P340, P305, P351, P338
Product Description:
Highly potent and selective irreversible MALT1 inhibitor (IC50=5.8µM). Binds directly to MALT1 and suppresses protease function. Decreases NF-kappaB activity induced by MALT1. Inhibits cell proliferation and MALT1-mediated cleavage activity. Suppresses human TMD8 and HBL-1 (EC50= ~200nM and ~500nM for HBL-1 and TMD8, respectively) activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) cell lines in vitro and xenotransplanted mouse ABC-DLBCL tumors in vivo and primary human ABC-DLBCLs ex vivo. In combination with bryostatin 1 displays selective killing of HIV latently infected CD4+ T cells. Inhibits NF-kappaB and NLRP3 inflammasome activation in macrophages. Decreased production of IL-1beta/IL-18 in PMA-differentiated THP-1 cells and bone marrow derived macrophage via suppressing the activation of NF-kappaB and NLRP3 inflammasome.
Purity:
>98%
Signal word:
Warning
SMILES:
COCCOC1=NN(C2=CC=C(NC(CCl)=O)C=C2)C(C3=CC=C(Cl)C(Cl)=C3)=N1
Solubility Chemicals:
Soluble in DMSO (30mg/ml) or ethanol (5mg/ml).
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo: L. Fontan, et al.; Cancer Cell 22, 812 (2012) | MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-kappaB and NLRP3 inflammasome activation: W. Liu, et al.; Oncotarget 7, 30536 (2016) | Short Communication: Preferential Killing of HIV Latently Infected CD4(+) T Cells by MALT1 Inhibitor: H. Li, et al.; AIDS Res. Hum. Retroviruses 32, 174 (2016)
Related Products
| Product Name | Product Code | Supplier | Genistein | AG-CN2-0427 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|